Effectiveness of testosterone replacement therapy in case of type 2 diabetes mellitus and male hypogonadism (metabolic and antioxidant evaluation)
AbstractThe risk of hypogonadism in male patients with diabetes mellitus type 2 (T2DM) exceeds the General population. Meanwhile, the
development in the patient with type 2 diabetes mellitus male hypogonadism, diagnosed by reducing the level of total testosterone
less than 12 nmol/l, contributes to the progression of existing metabolic disorders. Use in the absence of contraindications,
testosterone replacement therapy in T2DM patients and male hypogonadism as a rule, allows to break the vicious metabolic circle –
due to positive metabolic and anti-oxidant properties hormone testosterone.
Keywords:type 2 diabetes mellitus, testosterone deficiency, androgenotherapy, oxidative stress
Dear readers!
Full-text version of the article is available only in paper version.